MX355396B - Peptido - mimeticos de la horquilla beta. - Google Patents

Peptido - mimeticos de la horquilla beta.

Info

Publication number
MX355396B
MX355396B MX2014014840A MX2014014840A MX355396B MX 355396 B MX355396 B MX 355396B MX 2014014840 A MX2014014840 A MX 2014014840A MX 2014014840 A MX2014014840 A MX 2014014840A MX 355396 B MX355396 B MX 355396B
Authority
MX
Mexico
Prior art keywords
cys11
xaa14
xaa15
xaa13
xaa6
Prior art date
Application number
MX2014014840A
Other languages
English (en)
Other versions
MX2014014840A (es
Inventor
Obrecht Daniel
Otto Gombert Frank
Zimmermann Johann
Lederer Alexander
Oefner Christian
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MX2014014840A publication Critical patent/MX2014014840A/es
Publication of MX355396B publication Critical patent/MX355396B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula general ciclo (-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr1 0-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), el enlace disulfuro entre Cys4 y Cys11, y las sales aceptables farmacéuticamente del mismo, con Xaa3 es Try; Try(Me); o Tyr (CF3), Try(Me) es ácido (2S)-2-amino-(4-metoxifenil)-3-propionico, Tyr (CF3) es ácido (2S)-2-amino-(4-trifluorometoxifenil)-3-propionico, Xaa6 es Ala; o Acc Acc es ácido 1-aminociclopropano-carboxílico, Xaa8 es Orn (iPr), Orn(iPr) es ácido (2S)-Nw-isopropil-2,5-diaminopentanoico, Xaa13 es Gln; o Glu, Xaa14 es Lys (iPr), Lys(iPr) es ácido (2S)-Nw-isopropil-2,6-diaminohexanoico, Xaa15 es DPro; o DLys(iPr) , Dlys (iPr) es ácido (2R)-Nw-isopropil-2,6-diaminohexan oico, con la provisión de que si Xaa6 es Ala, entonces Xaa15 es DLys (iPr).
MX2014014840A 2012-06-06 2012-06-06 Peptido - mimeticos de la horquilla beta. MX355396B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/060766 WO2013182240A1 (en) 2012-06-06 2012-06-06 Beta-hairpin peptidomimetics

Publications (2)

Publication Number Publication Date
MX2014014840A MX2014014840A (es) 2015-02-12
MX355396B true MX355396B (es) 2018-04-18

Family

ID=46208596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014840A MX355396B (es) 2012-06-06 2012-06-06 Peptido - mimeticos de la horquilla beta.

Country Status (13)

Country Link
US (2) US9617308B2 (es)
EP (1) EP2859012B1 (es)
JP (1) JP6047231B2 (es)
CN (1) CN104603145B (es)
AU (1) AU2012381808B2 (es)
CA (1) CA2875733C (es)
ES (1) ES2647076T3 (es)
HK (1) HK1207867A1 (es)
IL (1) IL235946B (es)
IN (1) IN2014KN02752A (es)
MX (1) MX355396B (es)
SG (1) SG11201407837WA (es)
WO (1) WO2013182240A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641372B (zh) 2007-02-28 2012-11-28 波利弗尔有限公司 模板固定的肽模拟物
CN104603145B (zh) * 2012-06-06 2018-05-18 波利弗尔股份公司 β-发夹肽模拟物
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CA2960778C (en) 2014-09-11 2023-03-07 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
AU2017268291B2 (en) 2016-05-19 2022-09-29 Bristol-Myers Squibb Company PET-imaging immunomodulators
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
IL302979A (en) 2020-11-19 2023-07-01 Spexis Ag Pharmaceutical combinations containing peptide CXCR4 inhibitor and taxane for cancer treatment
WO2022184320A2 (en) 2021-03-03 2022-09-09 Spexis Ag Medical use of cyclic peptides
WO2023285681A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
WO2023285677A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212288A (en) * 1990-02-20 1993-05-18 Syntex (U.S.A.) Inc. Temporary minimal protection synthesis of serine-containing polypeptides
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
KR20090041360A (ko) * 2006-02-27 2009-04-28 테크니쉐 유니베르시테트 뮌헨 암 영상화 및 치료방법
CN101641372B (zh) * 2007-02-28 2012-11-28 波利弗尔有限公司 模板固定的肽模拟物
WO2010127704A1 (en) * 2009-05-07 2010-11-11 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
WO2011066869A1 (en) * 2009-12-04 2011-06-09 Polyphor Ag Beta-hairpin peptidomimetics
WO2012168336A1 (en) * 2011-06-07 2012-12-13 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
CN104603145B (zh) * 2012-06-06 2018-05-18 波利弗尔股份公司 β-发夹肽模拟物

Also Published As

Publication number Publication date
US20170165319A1 (en) 2017-06-15
MX2014014840A (es) 2015-02-12
WO2013182240A1 (en) 2013-12-12
US20150218219A1 (en) 2015-08-06
HK1207867A1 (en) 2016-02-12
ES2647076T3 (es) 2017-12-19
SG11201407837WA (en) 2014-12-30
NZ702470A (en) 2016-12-23
CA2875733C (en) 2019-09-10
AU2012381808A1 (en) 2015-01-22
JP2015521204A (ja) 2015-07-27
AU2012381808B2 (en) 2017-04-27
EP2859012B1 (en) 2017-08-09
IN2014KN02752A (es) 2015-05-08
JP6047231B2 (ja) 2016-12-21
US10363284B2 (en) 2019-07-30
EP2859012A1 (en) 2015-04-15
IL235946A0 (en) 2015-01-29
CN104603145A (zh) 2015-05-06
US9617308B2 (en) 2017-04-11
IL235946B (en) 2019-06-30
CN104603145B (zh) 2018-05-18
CA2875733A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
MX2014014840A (es) Peptido - mimeticos de la horquilla beta.
MX343205B (es) Peptidomiméticos de horquilla beta como antagonistas de cxc4.
MX2009008843A (es) Peptidomimeticos fijados a un patron.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2013079701A3 (en) Expression of mirnas in placental tissue
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
JP2012041342A5 (es)
EA201890236A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
MX363050B (es) Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune.
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
WO2013106385A3 (en) System and methods for determining tissue elasticity
GB2546224A (en) Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
ES2421717T3 (es) Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
CN104548194A (zh) 一种医用高性能粘合剂
NZ702666A (en) A method of weight reduction
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
CN205357113U (zh) 割草机刀架盘
RU2010127731A (ru) Способ лечения гнойно-воспалительных осложнений у онкоурологических больных
UA130761U (uk) Спосіб лікування ендометриту, індукованого генітальною герпесвірусною інфекцією
WO2012178151A3 (en) St6gal i mediated modulation of hematopoiesis

Legal Events

Date Code Title Description
FG Grant or registration